Abstract
To provide practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands. This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). Positron emission tomography (PET) using somatostatin receptor (SSTR) ligands can detect meningioma tissue with high sensitivity and specificity and may provide clinically relevant information beyond that obtained from structural magnetic resonance imaging (MRI) or computed tomography (CT) imaging alone. SSTR-directed PET imaging can be particularly useful for differential diagnosis, delineation of meningioma extent, detection of osseous involvement, and the differentiation between posttherapeutic scar tissue and tumour recurrence. Moreover, SSTR-peptide receptor radionuclide therapy (PRRT) is an emerging investigational treatment approach for meningioma. These practice guidelines will define procedure standards for the application of PET imaging in patients with meningiomas and related SSTR-targeted PRRTs in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers, facilitate comparability of studies, and to collect larger databases. The current document provides additional information to the evidence-based recommendations from the PET/RANO Working Group regarding the utilization of PET imaging in meningiomas Galldiks (Neuro Oncol. 2017;19(12):1576-87). The information provided should be considered in the context of local conditions and regulations.
Overview
- The study aims to develop joint practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands. The study was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO).
- The methodology used for the experiment includes positron emission tomography (PET) using somatostatin receptor (SSTR) ligands to detect meningioma tissue with high sensitivity and specificity. The study also includes SSTR-directed PET imaging to differentiate between posttherapeutic scar tissue and tumor recurrence, delineate meningioma extent, detect osseous involvement, and provide clinically relevant information beyond that obtained from structural magnetic resonance imaging (MRI) or computed tomography (CT) imaging alone. Additionally, the study discusses SSTR-peptide receptor radionuclide therapy (PRRT) as an emerging investigational treatment approach for meningioma.
Comparative Analysis & Findings
- The study compares the outcomes observed under different experimental conditions or interventions, including PET imaging using SSTR ligands and SSTR-directed PET imaging. The study identifies significant differences in the results between these conditions, such as the ability of SSTR-directed PET imaging to differentiate between posttherapeutic scar tissue and tumor recurrence, delineate meningioma extent, detect osseous involvement, and provide clinically relevant information beyond that obtained from structural MRI or CT imaging alone. The study also discusses the key findings of the study and how they relate to the initial hypothesis, such as the high sensitivity and specificity of PET imaging using SSTR ligands and the potential utility of SSTR-directed PET imaging for meningioma diagnosis and treatment.
Implications and Future Directions
- The study's findings have significant implications for the field of research or clinical practice, as they provide evidence for the utility of PET imaging using SSTR ligands and SSTR-directed PET imaging for meningioma diagnosis and treatment. The study identifies limitations, such as the need for larger databases and the need for further research to validate the findings. The study suggests possible future research directions, such as the development of standardized protocols for PET imaging using SSTR ligands and the exploration of the use of SSTR-directed PET imaging for meningioma monitoring and response assessment. The study also highlights the importance of considering local conditions and regulations when implementing these guidelines in clinical practice.